Abstract
Infliximab, a chimeric monoclonal anti-TNF-alfa agent used to treat autoimmune diseases, has shown a paradoxical side effect in the development of autoimmunity. We describe a case of alopecia areata universalis associated with infliximab treatment in a patient with Behçet disease. This case suggests a complex and contradictory role of TNF-α in the pathogenesis of alopecia areata.
MeSH terms
-
Adult
-
Alopecia Areata / chemically induced*
-
Alopecia Areata / immunology
-
Anti-Inflammatory Agents / adverse effects*
-
Anti-Inflammatory Agents / therapeutic use
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Autoimmune Diseases / chemically induced*
-
Autoimmune Diseases / immunology
-
Behcet Syndrome / drug therapy
-
Humans
-
Infliximab
-
Male
-
Off-Label Use
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Tumor Necrosis Factor-alpha
-
Infliximab